Archive: Company News
Company News: ISA Pharmaceuticals Advances Personalized Cancer Treatment
– Next-generation immunotherapy called MyISA® for individual cancer patients
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the recently established Tumor neoantigEn SeLection Alliance (TESLA), a global cancer neoantigen alliance forged by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute, which was announced on December 1st, 2016.
Company News: Curetis Publishes Business and Financial Update for the First Nine Months 2016
– U.S. FDA trial completed with excellent top-line data
– Leading position in genetic antimicrobial resistance biomarker testing strengthened by GEAR acquisition
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2016 and provided an outlook to coming months.
Company News: World Antibiotics Day: Reduction of infection risk in femoral head fractures by 66% with antibiotic-loaded bone cement from Heraeus
– New study from Great Britain verifies the advantages of antibiotic-loaded bone cement from Heraeus with femoral head fractures
– Older patients with concomitant diseases profit from locally applied antibiotics
Good news for World Antibiotics Day on November 18th. As local substances carriers, antibiotic-loaded bone cements from Heraeus help in the battle against implant-associated infections in orthopaedics and trauma surgery to prevent infection. This is demonstrated by a new randomised study* from Great Britain in which the use of double-loaded antibiotic bone cement following femoral head fracture led to a significant 66% reduction in infection risk with primary hip arthroplasties, as compared with bone cement with only one antibiotic.
Company News: Curetis Announces Positive Top Line Data from U.S. FDA Trial
– Primary endpoint for Unyvero LRT product for lower respiratory tract infections shows overall weighted average sensitivity of 90.2% and overall weighted average specificity of 99.3%
– U.S. FDA submission being prepared
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced top line data from its successfully completed Unyvero U.S. FDA trial. The trial was designed to compare the performance of the Unyvero Instrument Platform and the Unyvero LRT Lower Respiratory Tract Cartridge in detecting lower respiratory tract infections to microbiology culture, the current diagnostic standard of care.